News
J&J's Rybrevant Faspro moves beyond lung cancer with FDA nod
The FDA has approved Johnson & Johnson's Rybrevant Faspro for head and neck cancer, extending the franchise beyond lung cancer for the first time.
Oncology
Lung cancer vaccine renews synthetic DNA discussions
pharmaphorum spoke with Dr Amy Walker, CEO of 4basebio, about personalised cancer vaccines and synthetic DNA.
Oncology
How precision medicine treats an overlooked clinical variabl...
In oncology, time is not simply a measure of care; it is a clinical variable – and increasingly a therapeutic challenge.
News
Bayer's Hyrnuo moves first-line for lung cancer in China
Bayer's oral HER2 inhibitor Hyrnuo has been approved in China as a frontline therapy for advanced, HER2-mutant non-small cell lung cancer.
News
UK biotechs T-Therapeutics and Alethio score big financings
Two up-and-coming UK biotechs – T-Therapeutics and Alethio Therapeutics – have raised $133m and $90m, respectively, in impressive financing rounds.
News
Views & Analysis
Deep Dive
Editor's Picks
Editor's Picks
